Armodafinil (Nuvigil®) is an eugeroic drug made by Cephalon, FDA-approved 6/15/2007. Clinical trials for its use in bipolar disorder, cognition in schizophrenia, excessive fatigue in Parkinson's & cancer, begin. Patent expires 2023.
Armodafinil From Wikipedia, the free encyclopedia Jump to: navigation, search Armodafinil Systematic (IUPAC) name (-)-2-[(R)-(diphenylmethyl)sulfinyl]acetamide Identifiers CAS number 68693-11-8 ATC code N06BA07 PubChem ? Chemical data Formu
Modafinil induces wakefulness, but its dopamine-releasing action in the nucleus accumbens is weak and dose-dependent; no likelihood of euphoric response ('abuse potential').
Unlike conventional stimulants, no anxiety, agitation and insomnia; selectively stimulates brain's adrenergic receptors for norepinephrine (noradrenaline), a neurotransmitter linked to alertness, learning, and memory.
Accounts of use for depression, ADD/ADHD, fibromyalgia, chronic fatigue (off-label). Metabolic precursor to modafinil; takes 1 hr to kick in, hard on liver. Not "controlled" like modafinil/Provigil.
For narcolepsy, or off-label for depression, night-shift work, ADHD/ADD...a prodrug, metabolizes to modafinil (Provigil®), resulting in nearly identical pharmacological effects, takes 45-60 minutes to reach active levels in bloodstream.
In 10 to 20 years we'll be able to pharmacologically turn sleep off. It's already being quelled with Modafinil, a stimulant with a near-mythical reputation for keeping you awake without the jitters, excessive euphoria, and eventual crash that come after